Tango Therapeutics (TNGX) Return on Equity: 2021-2025
Historic Return on Equity for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to -0.68%.
- Tango Therapeutics' Return on Equity fell 16.00% to -0.68% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.68%, marking a year-over-year decrease of 16.00%. This contributed to the annual value of -0.58% for FY2024, which is 17.00% down from last year.
- Per Tango Therapeutics' latest filing, its Return on Equity stood at -0.68% for Q3 2025, which was up 29.38% from -0.96% recorded in Q2 2025.
- Tango Therapeutics' Return on Equity's 5-year high stood at -0.16% during Q4 2021, with a 5-year trough of -8.70% in Q2 2021.
- For the 3-year period, Tango Therapeutics' Return on Equity averaged around -0.56%, with its median value being -0.49% (2023).
- Per our database at Business Quant, Tango Therapeutics' Return on Equity surged by 841bps in 2022 and then crashed by 51bps in 2025.
- Tango Therapeutics' Return on Equity (Quarterly) stood at -0.16% in 2021, then decreased by 25bps to -0.41% in 2022, then climbed by 3bps to -0.38% in 2023, then fell by 22bps to -0.61% in 2024, then declined by 16bps to -0.68% in 2025.
- Its Return on Equity stands at -0.68% for Q3 2025, versus -0.96% for Q2 2025 and -0.72% for Q1 2025.